Hematopoietic Stem Cell Mobilization
"Hematopoietic Stem Cell Mobilization" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Descriptor ID |
D019650
|
MeSH Number(s) |
E02.095.410
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hematopoietic Stem Cell Mobilization".
Below are MeSH descriptors whose meaning is more specific than "Hematopoietic Stem Cell Mobilization".
This graph shows the total number of publications written about "Hematopoietic Stem Cell Mobilization" by people in this website by year, and whether "Hematopoietic Stem Cell Mobilization" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 2 | 3 |
1998 | 4 | 2 | 6 |
1999 | 7 | 5 | 12 |
2000 | 3 | 3 | 6 |
2001 | 2 | 3 | 5 |
2002 | 3 | 2 | 5 |
2003 | 4 | 1 | 5 |
2004 | 1 | 0 | 1 |
2006 | 2 | 1 | 3 |
2007 | 1 | 4 | 5 |
2008 | 1 | 3 | 4 |
2009 | 5 | 0 | 5 |
2010 | 2 | 0 | 2 |
2011 | 3 | 1 | 4 |
2012 | 4 | 1 | 5 |
2013 | 6 | 1 | 7 |
2014 | 3 | 1 | 4 |
2015 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2017 | 4 | 1 | 5 |
2018 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
2020 | 3 | 2 | 5 |
2021 | 1 | 0 | 1 |
2022 | 1 | 3 | 4 |
2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hematopoietic Stem Cell Mobilization" by people in Profiles.
-
Evaluating the efficiency and safety of large-volume leukapheresis using the Spectra Optia continuous mononuclear cell collection protocol for peripheral blood stem cell collection from healthy donors: A retrospective study. Transfusion. 2023 11; 63(11):2120-2130.
-
Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. 2023 08 01; 108(8):2249-2254.
-
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023 04; 29(4):869-879.
-
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10.
-
Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplant Cell Ther. 2023 01; 29(1):37.e1-37.e7.
-
Successful haematopoietic progenitor cell collection by plerixafor in combination with reduced dose granulocyte colony-stimulating factor for severe hypoxemia provoked by high-dose granulocyte colony-stimulating factor administration. Transfus Med. 2022 12; 32(6):527-529.
-
Low hematocrit reduces the efficiency of CD34+ cell collection when using the Spectra Optia continuous mononuclear cell collection procedure. Transfusion. 2022 05; 62(5):1065-1072.
-
Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. Transplant Cell Ther. 2021 06; 27(6):503.e1-503.e8.
-
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. Leuk Lymphoma. 2021 06; 62(6):1441-1449.
-
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer. 2021 04 15; 127(8):1246-1259.